Source: Illustration: Niklas Elmehed. Copyright: Nobel Media AB 2018
Kymab congratulates Sir Greg Winter on his Nobel prize and thanks him for his major contribution to making the therapeutic use of human antibodies a reality
Nobel Prize is awarded to co-founder of CAT Sir Greg Winter whose work with Dr Dave Chiswell (Kymab’s CEO) and others opened therapeutic antibody approaches.
On 3 October 2018, the Nobel prize for Chemistry was awarded to three researchers whose work on engineering proteins led to a revolution in antibody development to treat human diseases; a movement that Kymab is at the forefront of today.
Sir Greg Winter, of the MRC Laboratory of Molecular Biology, Cambridge, UK, shared one half of the award. Sir Greg was co-founder of Cambridge Antibody Technology (CAT) with Kymab CEO, Dr Dave Chiswell.
Speaking to the journal Nature on the date of the announcement about the foundation of CAT in 1989, Dr Chiswell said CAT was "one of the earliest generations of European biotechs."
Dr Chiswell said those early days were "exciting times because we didn’t know what we were doing and nobody in the world believed that antibodies were really good." CAT went on to develop the first human antibody isolated by phage display, Humira, the world’s largest-selling drug, with sales of $18.4 billion in 2017.
The three laureates are: Frances Arnold, at the California Institute of Technology in Pasadena, who is awarded a half share; and Sir Winter and professor George Smith, from the University of Missouri in Columbia, who share the remaining half.
Nobel Prize press release: https://www.nobelprize.org/prizes/chemistry/2018/press-release
Nature report: https://www.nature.com/articles/d41586-018-06753-y
October 1990 publication contributing to the Nobel Prize: https://www.nature.com/articles/348552a0.pdf